Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARK3 | P27448 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.43 |
| ▸ | TTK | P33981 | 2/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.40 |
| ▸ | MMP12 | P39900 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26857023 | 0.86 | PIK3CG (0.41) | PIK3CGPIK3CAPIK3CDPIK3CBTTK | |
| SCHEMBL26857149 | 0.86 | ALDH1A1 (0.43) | MARK3PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL26856891 | 0.86 | PIK3CG (0.49) | PIK3CGPIK3CAPIK3CDPIK3CBTTK | |
| SCHEMBL26856882 | 0.85 | MMP12 (0.53) | PIK3CGPIK3CDPIK3CBTTKMMP12 | |
| SCHEMBL26857084 | 0.85 | PIK3CG (0.39) | PIK3CGPIK3CAPIK3CDPIK3CBTTK | |
| SCHEMBL26857089 | 0.85 | MAPK1 (0.39) | MARK3PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL26857092 | 0.84 | TTK (0.40) | MARK3PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL26857327 | 0.84 | PIK3CG (0.44) | MARK3PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL26857153 | 0.84 | MMP12 (0.42) | PIK3CGPIK3CAPIK3CDPIK3CBTTK | |
| SCHEMBL26856916 | 0.83 | PIK3CG (0.46) | PIK3CGPIK3CAPIK3CDPIK3CBTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | SNCA, PSEN2, PARK7 | MARK3 834/4885PIK3CG 690/4885PIK3CA 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.